Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.50 |
| ▸ | MTOR | P42345 | 3/20 | 0.50 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCND3 | P30281 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | PRKCH | P24723 | 1/20 | 0.39 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660579 | 1.00 | PIK3CA (0.50) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL18291561 | 0.82 | CCNT1 (0.46) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL3125646 | 0.79 | DDB1 (0.46) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL31058076 | 0.78 | WNT3A (0.45) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL20249114 | 0.78 | CCNT1 (0.46) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL18291708 | 0.78 | SMN1; SMN2 (0.42) | PIK3CAMTORCCNT1CDK4CCND1 | |
| SCHEMBL29660541 | 0.77 | MAPT (0.59) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL12302651 | 0.77 | MAPT (0.59) | CCNT1CDK4CCND1CCND3CDK9 | |
| SCHEMBL1992377 | 0.77 | CHRNB2 (0.64) | CDK4CCND1CHRNB2CHRNA4PIM1 | |
| SCHEMBL1269255 | 0.76 | PIK3CA (0.43) | PIK3CAMTORCHRNB2CHRNA4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-11-03 | — | — | US | disclosed |
| EP-4013743-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114502536-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| WO-2021030623-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | NOVARTIS AG (CH) | 2019-04-09 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-8546396-B2 | N-(hetero)aryl, 2-(hetero)aryl—substituted acetamides for use as Wnt signaling modulators | IRM LLC (BM) | 2013-10-01 | — | — | US | disclosed |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS (GB) | 2013-07-18 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010101849-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2010-09-10 | — | — | WO | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | PIK3CA 108/4885MTOR 158/4885CCNT1 49/4885 |
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | PIK3CA 207/4885MTOR 117/4885CCNT1 44/4885 |
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | PIK3CA 176/4885MTOR 94/4885CCNT1 37/4885 |
| US-10251893-B2 | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as Wnt signaling modulators | WNT1, CTNNB1, CTNNA1 | PIK3CA 1634/4885MTOR 264/4885CCNT1 650/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | PIK3CA 1512/4885MTOR 287/4885CCNT1 868/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | PIK3CA 331/4885MTOR 117/4885CCNT1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.